Tagged with Investment,

Switzerland Michael Altorfer, CEO of the Swiss Biotech Association, a membership organisation representing the interests of the Swiss biotech industry, discusses the evolution of the biotech sector in Switzerland, how the country’s ecosystem has helped foster success stories like Actelion, and the multilateral work being done to improve intellectual property protection…

Switzerland In a recent conversation with PharmaBoardroom, Michael Sidler of Redalpine Venture Partners, a venture capital (VC) firm aiming to support founders and start-ups in Europe, highlighted how the European VC & the Switzerland Biotech Investment space has evolved over the past decade and the funding challenges that remain. He also…

Saudi Arabia Rubens Hannun, president of the Arab Brazilian Chamber of Commerce, discusses the commercial relationship between Brazil and Saudi Arabia, which now reaches over US USD three billion between imports and exports, the role of pharmaceuticals, the opportunities in halal products and their efforts to inform the Arab and Brazilian business…

Switzerland Redalpine Venture Partners’ Dr Michael Sidler highlights some of the key trends in the European biotech VC space, the funding and operational strategies that successful start-ups in Europe are utilising, and the Swiss innovation ecosystem.   What has happened in Europe over the last couple of decades has been truly…

Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download.   Long heralded as an innovation powerhouse able to hold its own against the…

China The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences.   AstraZeneca signs deal with Chinese biotech Junshi Biosciences to market anti-PD-1 cancer drug in China https://www.biopharma-reporter.com/Article/2021/03/01/AstraZeneca-betting-on-China-s-PD-1-cancer-market AstraZeneca has signed a…

India The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in the latest national budget; predictions of rapid growth in the coming decade; Cipla’s potential entry into the COVID-19 vaccine race; and Pfizer’s withdrawal of its emergency use application for its vaccine in India.…

Global The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the history of the pharmaceuticals industry. Not only do innovative therapies such as CAR-T herald a shift towards genuinely individualized medicine and an exciting new front in the war against cancer,…

Americas The Top 15 pharmaceutical companies in the Central America and Caribbean (CENCA) market list is dominated by familiar big pharma players. However, among the liked of Sanofi, Abbott, Bayer, Pfizer, AstraZeneca, and Novartis sits Megalabs – a Latin American player that has been able to establish itself as a regional…

Switzerland Giorgio Calderari, the chairman of Farma Industria Ticino, the association of chemical and pharmaceutical industries in the Swiss canton of Ticino, explains how a region with a population of 350,000 has managed to create a turnover of over two billion dollars, excelling as an innovative hub. Furthermore, he analyzes the…

Global David H. Crean summarizes the recent 39th annual J.P. Morgan Healthcare Conference 2021 that was held in a virtual format, noting potential changes in format for future events. Crean does, however, underline the importance of the Conference for industry networking and highlights some of the biopharma topics to watch under…

China 2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being discovered in China around the beginning of 2020, the country bounced back from the COVID-19 outbreaks by mid-year to deliver the hottest year for Chinese biopharma yet.   The Chinese biopharma sector…